Table 6. Ipilimumab-induced reactions of the respiratory tract and renal system.

side effect	onset (weeksafter start ofipilimumab)	treatmenta ofside effect	outcome ofside effect	age(years)	gender	primarytumor	stageb,c	previoussystemictherapies	metastasesbeforeipilimumab	remissionafteripilimumab	clinicalresponse
barky rhinitis	11	steroids	resolved	F	49	skin	IV	bevacizumab, temozolomide, DTIC, eldesine, platinol, paclitaxel, sorafenib	lung, liver, soft tissue, pancreas, LN, bones, skin, GIT	liver, LN	MR
alveolitis	3	steroids	resolved	M	59	unknown primary	IV	temozolomide	brain, lung	none	PD
persistent bronchitis(>3 months in summer)	17	antibiotics	resolved	M	38	skin	adjuvant	n/a	n/a	n/a	SD
dyspnea	14	inhalative steroids	resolved	F	44	skin	adjuvant	n/a	n/a	n/a	SD
intermittent dyspnea	39	steroids	resolved	M	64	skin	adjuvant	n/a	n/a	n/a	SD
cough, dyspnea, arthritis, myalgia, diarrhea, sweating, papular exanthema	1	acetylcysteine	resolved	M	48	skin	IV	IFN-α, DVP	LN, lung, liver, bone	LN, liver	PR
acute renal failure, interstitial nephritis, atypical pneumonia	6e, 10f	steroids, antibiotics	resolved	F	72	unknown primary	IV	DTIC, vaccination (PRAME)d	skin, LN	LN	PR
acute renal failure, atypical pneumonia, iridocyclitis/keratitis, deafness	8g, 10h	steroids (1 mg/kg )	resolvedi, permanent changesj	F	53	mucosal	IV	IFN-α, DTIC, sorafenib, carboplatin+paclitaxel, fotemustine	kidney, skin, paracolic area, spinal cord	kidney, skin, paracolic area, spinal cord	PR

^*case is detailed in the result section.

^alisted treatments are systemic treatments unless otherwise specified.

^btumor-free high-risk stage III melanoma (AJCC 2009); adjuvant administration of ipilimumab.

^cstage IV metastatic disease (AJCC 2009).

^dPRAME study; vaccination with GSK2302025A.

^eatypical pneumonia.

^facute renal failure.

^grenal failure/atypical pneumonia.

^hiridocyclitis/keratitis, deafness.

^Irenal failure/atypical pneumonia/iridocyclitis/keratitis.

^jdeafness.

M indicates male; F, female; LN, lymph nodes; IFN-α, interferon-α; DTIC, dacarbazine; DVP; polychemotherapy with dacarbazine/vindesine/paclitaxel; GIT, gastrointestinal tract; PR, partial response; SD, stable disease; MR, mixed response; PD, progressive disease.